| Title | Effects of Ginkgo biloba Extract EGb 761((R)) on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. | | Author(s) | Scripnikov A, Khomenko A, Napryeyenko O, for the GINDEM-NP Study Group | | Institution | Chair of Psychiatry, Poltava Regional Psychiatry Hospital, Poltava, Ukraine. | | Source | Wien Med Wochenschr 2007 Jul; 157(13-14):295-300. | | Abstract | In a randomised, double-blind, 22-week trial 400 patients with dementia associated with neuropsychiatric features were treated with Ginkgo biloba extract EGb 761((R)) (240 mg/day) or placebo. Patients with probable Alzheimer's disease, possible Alzheimer's disease with cerebrovascular disease or vascular dementia were eligible if they scored 9 to 23 on the SKT cognitive test battery and at least 5 on the Neuropsychiatric Inventory (NPI). EGb 761((R)) was significantly superior to placebo with respect to the primary (SKT test battery) and all secondary outcome variables. The mean composite score (frequency x severity) and the mean caregiver distress score of the NPI dropped from 21.3 to 14.7 and 13.5 to 8.7, respectively, in the EGb 761((R))-treated patients, but increased from 21.6 to 24.1 and 13.4 to 13.9, respectively, under placebo (p < 0.001). The largest drug-placebo differences in favour of EGb 761((R)) were found for apathy/indifference, anxiety, irritability/lability, depression/dysphoria and sleep/nighttime behaviour. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 17704975 |
|
